Flputnam Investment Management Co. Has $1.79 Million Holdings in Zoetis Inc. (NYSE:ZTS)

Flputnam Investment Management Co. cut its position in Zoetis Inc. (NYSE:ZTS) by 15.6% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 9,046 shares of the company’s stock after selling 1,675 shares during the period. Flputnam Investment Management Co.’s holdings in Zoetis were worth $1,785,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Blue Bell Private Wealth Management LLC boosted its position in Zoetis by 222.5% in the fourth quarter. Blue Bell Private Wealth Management LLC now owns 129 shares of the company’s stock valued at $25,000 after buying an additional 89 shares in the last quarter. Evermay Wealth Management LLC lifted its position in shares of Zoetis by 439.3% during the first quarter. Evermay Wealth Management LLC now owns 151 shares of the company’s stock worth $25,000 after purchasing an additional 123 shares in the last quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC lifted its position in shares of Zoetis by 430.8% during the first quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC now owns 138 shares of the company’s stock worth $26,000 after purchasing an additional 112 shares in the last quarter. Worth Asset Management LLC acquired a new position in shares of Zoetis during the first quarter worth approximately $26,000. Finally, Moisand Fitzgerald Tamayo LLC lifted its position in shares of Zoetis by 105.5% during the third quarter. Moisand Fitzgerald Tamayo LLC now owns 187 shares of the company’s stock worth $33,000 after purchasing an additional 96 shares in the last quarter. 92.80% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

ZTS has been the topic of a number of research reports. The Goldman Sachs Group upped their target price on shares of Zoetis from $190.00 to $226.00 and gave the stock a “buy” rating in a research report on Wednesday, January 17th. StockNews.com lowered shares of Zoetis from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, February 20th. Barclays upped their target price on shares of Zoetis from $255.00 to $260.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 14th. Stifel Nicolaus dropped their price target on shares of Zoetis from $215.00 to $195.00 and set a “buy” rating for the company in a research note on Tuesday, April 2nd. Finally, Jefferies Financial Group reissued a “buy” rating and set a $230.00 price target on shares of Zoetis in a research note on Tuesday, December 19th. Eight analysts have rated the stock with a buy rating, According to MarketBeat, Zoetis has an average rating of “Buy” and a consensus price target of $221.75.

Insider Buying and Selling at Zoetis

In other Zoetis news, EVP Roxanne Lagano sold 923 shares of the company’s stock in a transaction that occurred on Thursday, January 18th. The shares were sold at an average price of $191.43, for a total value of $176,689.89. Following the completion of the sale, the executive vice president now owns 17,569 shares of the company’s stock, valued at $3,363,233.67. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Over the last 90 days, insiders sold 2,209 shares of company stock valued at $408,453. Corporate insiders own 0.15% of the company’s stock.

Zoetis Stock Up 2.2 %

Shares of NYSE:ZTS opened at $153.02 on Wednesday. Zoetis Inc. has a 52 week low of $148.48 and a 52 week high of $201.92. The company has a debt-to-equity ratio of 1.32, a quick ratio of 2.00 and a current ratio of 3.36. The company has a market capitalization of $69.99 billion, a PE ratio of 30.18, a PEG ratio of 2.29 and a beta of 0.85. The company has a 50 day moving average price of $178.25 and a two-hundred day moving average price of $180.59.

Zoetis (NYSE:ZTS) last issued its earnings results on Tuesday, February 13th. The company reported $1.24 EPS for the quarter, missing the consensus estimate of $1.32 by ($0.08). Zoetis had a net margin of 27.43% and a return on equity of 51.25%. The firm had revenue of $2.21 billion during the quarter, compared to the consensus estimate of $2.19 billion. During the same period in the previous year, the company posted $1.15 EPS. The firm’s revenue for the quarter was up 8.5% on a year-over-year basis. Analysts forecast that Zoetis Inc. will post 5.8 earnings per share for the current year.

Zoetis Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, June 4th. Shareholders of record on Friday, April 19th will be paid a $0.432 dividend. This represents a $1.73 annualized dividend and a yield of 1.13%. The ex-dividend date of this dividend is Thursday, April 18th. Zoetis’s payout ratio is presently 34.12%.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.